Stock 1477 OCUMENSION THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Ocumension Therapeutics Stock

Equities

1477

KYG674111011

Pharmaceuticals

Delayed Hong Kong S.E.
Other stock markets
 09:50:20 2024-05-06 pm EDT 		5-day change 1st Jan Change
7.21 HKD -1.23% Intraday chart for Ocumension Therapeutics +0.97% +8.53%
Apr. 15 Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug MT
Apr. 15 Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China CI
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 444M 61.55M 481M Sales 2025 * 809M 112M 878M Capitalization 4.67B 648M 5.06B
Net income 2024 * -251M -34.83M -272M Net income 2025 * -3M -416K -3.25M EV / Sales 2024 * 8.41 x
Net cash position 2024 * 937M 130M 1.02B Net cash position 2025 * 969M 134M 1.05B EV / Sales 2025 * 4.57 x
P/E ratio 2024 *
-18.7 x
P/E ratio 2025 *
-89.7 x
Employees 444
Yield 2024 *
-
Yield 2025 *
-
Free-Float 47.57%
More Fundamentals * Assessed data

Chart Ocumension Therapeutics

Dynamic Chart

Latest news about Ocumension Therapeutics

Ocumension Therapeutics Completes Phase III Trials for Postoperative Inflammation Drug MT
Ocumension Therapeutics Announces Phase III Clinical Trial of OT-502 in China CI
Ocumension Therapeutics' Eye Drug Completes Clinical Trials, to Apply for NDA Soon MT
Ocumension Therapeutics Announces Completion of the Phase III Clinical Trial of OT-702 in China CI
Ocumension Therapeutics’ Loss for 2023 Narrows; Shares Down 4% MT
Ocumension Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ocumension Therapeutics' Phase 2 Trial for Dry Eye Treatment Meets Clinical Endpoints MT
Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202 CI
Ocumension Therapeutics Cuts Shareholding in Nasdaq-Listed EyePoint Pharmaceuticals MT
Ocumension Therapeutics Gets Nod to Register Iluvien in Hong Kong MT
Ocumension Therapeutics Receives Approval for Marketing OT-703 in Hong Kong CI
Ocumension Therapeutics commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023. CI
Ocumension Says Core Product Added to China's National Reimbursement Drug List MT
China Includes Ocumension's Middle Eye Infection Treatment in Drug Reimbursement List MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing MT
More news

Analyst Recommendations on Ocumension Therapeutics

UBS Adjusts Ocumension Therapeutics’ Price Target to HK$15.90 From HK$23.20, Keeps at Buy MT
More recommendations

Press releases Ocumension Therapeutics

OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth PR
Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones AQ
Ocumension Therapeutics Announces 2023 Interim Results AQ
Nicox's Partner Ocumension Therapeutics Receives Priority Review Status for ZERVIATE New Drug Application in China AQ
Nicox, 2023 Ordinary Shareholder Meeting to be held on June 1st, 2023 AQ
More press releases

News in other languages on Ocumension Therapeutics

Nicox: trésorerie de 21,4 millions d’euros à fin mars, visibilité jusqu’au deuxième trimestre 2024
Nicox: demande d'autorisation du Zerviate en Chine pour 2024
Nicox : le titre s'envole, avancée sur Zerviate en Chine
Nicox : données d'étude positives pour Zerviate en Chine
La valeur du jour à Paris Nicox : renforcement de la protection intellectuelle de Zerviate en Europe
More news

Quotes and Performance

1 day+2.10%
1 week+7.20%
Current month+1.67%
1 month+30.36%
3 months+43.70%
6 months-5.81%
Current year+9.28%
More quotes

Highs and lows

1 week
7.01
Extreme 7.01
7.54
1 month
5.50
Extreme 5.5
7.54
Current year
4.51
Extreme 4.51
7.54
1 year
4.51
Extreme 4.51
10.40
3 years
4.51
Extreme 4.51
32.05
5 years
4.51
Extreme 4.51
43.00
10 years
4.51
Extreme 4.51
43.00
More quotes

Managers and Directors - Ocumension Therapeutics

Managers TitleAgeSince
Ye Liu CEO
 Chief Executive Officer 53 18-07-31
Tim Ruan DFI
 Director of Finance/CFO 38 23-01-11
Dong Hong Chen CTO
 Chief Tech/Sci/R&D Officer 53 19-10-27
Members of the board TitleAgeSince
Wei Li BRD
 Director/Board Member 52 18-03-31
Yan Ling Cao BRD
 Director/Board Member 39 19-06-17
Ting Yuk Wu BRD
 Director/Board Member 69 20-06-22
More insiders

ETFs positioned on Ocumension Therapeutics

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.59% 4 M€ -27.92%
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +3.34% -
More ETFs positioned on Ocumension Therapeutics

Quotes

Date Price Change Volume
24-05-06 7.21 -1.23% 156 479
24-05-06 7.3 +2.10% 2,950,500
24-05-03 7.15 -4.03% 834,000
24-05-02 7.45 +3.76% 614,500
24-04-30 7.18 +5.43% 2,518,275

Delayed Quote Hong Kong S.E., May 06, 2024 at 04:08 am EDT

More quotes

Company Profile

Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Ocumension Therapeutics

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
6.731 CNY
Average target price
7.77 CNY
Spread / Average Target
+15.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
OCUMENSION THERAPEUTICS Stock Ocumension Therapeutics
+9.28% 635M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.52% 662B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.96% 546B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.21% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.02% 323B
ABBVIE INC. Stock AbbVie Inc.
+5.01% 289B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
NOVARTIS AG Stock Novartis AG
+3.81% 198B
ROCHE HOLDING AG Stock Roche Holding AG
-10.63% 194B
AMGEN INC. Stock Amgen Inc.
+3.98% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 1477 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW